Last updated: February 28, 2026
What is the product associated with NDC 49348-0757?
NDC 49348-0757 refers to Eptinezumab, marketed as Vyepti. It is a monoclonal antibody developed by Lundbeck and AstraZeneca for the preventive treatment of migraines in adults.
What is the current market landscape?
Market Size and Growth
- The global migraine therapeutics market was valued at approximately USD 3 billion in 2021.
- Expected compound annual growth rate (CAGR): 4-6% through 2027 (source: MarketWatch).
- The migraine preventive segment accounts for roughly 60% of this market.
Competitive Positioning
- Vyepti is among three FDA-approved monoclonal antibodies targeting calcitonin gene-related peptide (CGRP): Erenumab (Aimovig), Fremanezumab (Ajovy), and Galcanezumab (Emgality).
- Vyepti received FDA approval in April 2020 for migraine prevention.
- Its administration route is intravenous, distinct from subcutaneous options, impacting patient preference and provider adoption.
Market Penetration
- Initial adoption has been steady, with early prescriptions primarily within specialized neurology clinics.
- Market share in this segment: estimated 15-20% among CGRP inhibitors as of late 2022.
- Growth potential depends on expanding prescriber awareness, infusion service infrastructure, and payor reimbursement policies.
Price and Reimbursement Dynamics
List Price and Wholesale Acquisition Cost (WAC)
- In the U.S., Vyepti's WAC is approximately USD 6,500 per infusion.
- Dosing: 100 mg administered via IV every 12 weeks; some patients require 300 mg dosing, increasing per-infusion costs proportionally.
Cost Comparison with Competitors
| Drug |
Administration |
WAC per infusion |
Annual Cost (assuming quarterly dosing) |
| Vyepti (NDC: 49348-0757) |
IV 100 mg or 300 mg |
USD 6,500-19,500 |
USD 26,000 - USD 78,000 |
| Aimovig |
Subcutaneous |
USD 6,600/month |
USD 79,200 |
| Ajovy |
Subcutaneous |
USD 6,000/month |
USD 72,000 |
| Emgality |
Subcutaneous |
USD 6,600/month |
USD 79,200 |
Reimbursement Environment
- Insurance coverage varies, with nationally contracted payors covering infusion costs under outpatient services.
- Out-of-pocket costs for patients are generally USD 50–150 per infusion due to copay assistance programs.
Price Projections
Short-Term Outlook (Next 1-2 years)
- Price stability expected due to long patent life and steady demand.
- No significant price reductions anticipated unless biosimilar or alternative biologics enter the market.
Medium-Term Outlook (3-5 years)
Long-Term Perspective (5+ years)
- Price erosion possible if biosimilar or alternative therapies become available.
- Economies of scale and increased market penetration could lead to marginal price reductions.
Regulatory and Policy Factors
- Patent protection expires in 2028; biosimilar competition could emerge thereafter.
- CMS and private payors might impose step edits or formulary restrictions impacting pricing.
Consumer and Market Impacts
- The high treatment cost influences payor coverage and patient access.
- Manufacturers might introduce patient assistance programs to offset out-of-pocket expenses.
Key Anticipated Trends
- Increased utilization within neurology practices.
- Consolidation of market share among CGRP monoclonal antibodies.
- Pricing remains relatively stable over the near term due to limited biosimilar activity.
Summary
| Aspect |
Data Points |
| Current list price |
USD 6,500 per infusion |
| Market share (2022) |
15-20% among CGRP inhibitors |
| 2021 market size |
USD 3 billion globally |
| Growth rate |
4-6% CAGR through 2027 |
| Patent expiration |
2028 |
| Competition |
Limited biosimilar activity anticipated until post-2028 |
Key Takeaways
- NDC 49348-0757 (Vyepti) has established a steady growth trajectory within the migraine prophylactic market.
- Price stability over the next 2 years, with possible reductions as biosimilars approach.
- Competitive landscape is primarily composed of subcutaneous monoclonal antibodies, but the infusion route may sustain premium pricing.
- Reimbursement and access remains a critical factor influencing market penetration.
- Long-term pricing remains uncertain, contingent on biosimilar development, patent cliffs, and healthcare policy changes.
FAQs
1. What are the main factors influencing Vyepti’s pricing?
Market demand, competitive pressure from other CGRP inhibitors, reimbursement arrangements, and biosimilar development impact pricing.
2. How does Vyepti compare cost-wise to oral migraine prophylactics?
Oral options typically cost USD 1,000–3,000 annually, significantly lower than biologics, but may be less effective for all patient groups.
3. Is there potential for price reductions due to biosimilars?
Biosimilar development is unlikely before patent expiration in 2028; after that, biosimilar entry could trigger price competition.
4. How does administration route affect market adoption?
IV administration requires infusion services, adding logistical costs, but some clinicians prefer infusion for adherence; this influences market share dynamics.
5. What regulatory factors could impact future pricing?
Patent expirations and policy changes by CMS and private payors can influence reimbursement and, indirectly, pricing.
References
- MarketWatch. (2022). Migraine therapeutics market size & forecast.
- FDA. (2020). Vyepti (eptinezumab) approval announcement.
- IQVIA. (2022). U.S. biologics market overview.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement policy updates.
- Xcenda. (2021). Biologic pricing and biosimilar market analysis.
